Metropolitan Life Insurance Company (MetLife)’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-778
| Closed | -$208K | – | 1253 |
|
|
2024
Q1 | $208K | Sell |
778
-63
| -7% | -$14.8K | 0.01% | 698 |
|
|
2023
Q4 | $195K | Buy |
841
+56
| +7% | +$9.8K | 0.01% | 740 |
|
|
2023
Q3 | $115K | Buy |
785
+41
| +6% | +$7.72K | 0.01% | 936 |
|
|
2023
Q2 | $172K | Buy |
744
+63
| +9% | +$17.1K | 0.01% | 744 |
|
|
2023
Q1 | $165K | Sell |
681
-81
| -11% | -$22.1K | 0.01% | 740 |
|
|
2022
Q4 | $221K | Hold |
762
| – | – | 0.01% | 673 |
|
|
2022
Q3 | $49.5K | Hold |
762
| – | – | ﹤0.01% | 1464 |
|
|
2022
Q2 | $54.5K | Hold |
762
| – | – | ﹤0.01% | 1446 |
|
|
2022
Q1 | $74.8K | Sell |
762
-2,468
| -76% | -$208K | ﹤0.01% | 1378 |
|
|
2021
Q4 | $274K | Hold |
3,230
| – | – | ﹤0.01% | 1795 |
|
|
2021
Q3 | $258K | Hold |
3,230
| – | – | ﹤0.01% | 1895 |
|
|
2021
Q2 | $315K | Buy |
3,230
+690
| +27% | +$81.7K | ﹤0.01% | 1825 |
|
|
2021
Q1 | $297K | Sell |
2,540
-128
| -5% | -$14.9K | ﹤0.01% | 1752 |
|
|
2020
Q4 | $297K | Hold |
2,668
| – | – | ﹤0.01% | 1684 |
|
|
2020
Q3 | $317K | Hold |
2,668
| – | – | 0.01% | 1509 |
|
|
2020
Q2 | $302K | Hold |
2,668
| – | – | 0.01% | 1537 |
|
|
2020
Q1 | $178K | Hold |
2,668
| – | – | ﹤0.01% | 1659 |
|
|
2019
Q4 | $243K | Hold |
2,668
| – | – | ﹤0.01% | 1780 |
|
|
2019
Q3 | $230K | Buy |
2,668
+319
| +14% | +$29.9K | ﹤0.01% | 1784 |
|
|
2019
Q2 | $246K | Buy |
2,349
+87
| +4% | +$9.32K | ﹤0.01% | 1759 |
|
|
2019
Q1 | $283K | Hold |
2,262
| – | – | 0.01% | 1665 |
|
|
2018
Q4 | $255K | Hold |
2,262
| – | – | 0.01% | 1645 |
|
|
2018
Q3 | $484K | Buy |
2,262
+333
| +17% | +$83.6K | 0.01% | 1374 |
|
|
2018
Q2 | $540K | Buy |
1,929
+480
| +33% | +$84.3K | 0.01% | 1269 |
|
|
2018
Q1 | $169K | Hold |
1,449
| – | – | ﹤0.01% | 1996 |
|
|
2017
Q4 | $133K | Buy |
+1,449
| New | +$82.8K | ﹤0.01% | 2146 |
|
|
2015
Q3 | – | Sell |
-2,023
| Closed | -$158K | – | 2695 |
|
|
2015
Q2 | $158K | Buy |
+2,023
| New | +$170K | ﹤0.01% | 2522 |
|
|
2014
Q4 | – | Sell |
-1,739
| Closed | -$183K | – | 2668 |
|
|
2014
Q3 | $183K | Buy |
1,739
+200
| +13% | +$27.8K | ﹤0.01% | 2446 |
|
|
2014
Q2 | $220K | Buy |
1,539
+606
| +65% | +$88.6K | ﹤0.01% | 2451 |
|
|
2014
Q1 | $141K | Hold |
933
| – | – | ﹤0.01% | 2614 |
|
|
2013
Q4 | $171K | Hold |
933
| – | – | ﹤0.01% | 2571 |
|
|
2013
Q3 | $206K | Hold |
933
| – | – | ﹤0.01% | 2404 |
|
|
2013
Q2 | $163K | Buy |
+933
| New | +$243K | ﹤0.01% | 2489 |
|
Other funds holding MDGL
ACA
BBA
RI
PC
Metropolitan Life Insurance Company (MetLife)'s MDGL Position: Q2 2024 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2024, closing a stake of 778 shares — an estimated $208K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in MDGL in Q2 2013 and held it in 33 quarters. The position peaked at $540K in Q2 2018. 257 funds tracked by Wall St. Rank hold MDGL as of Q2 2024.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Madrigal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 778 Madrigal Pharmaceuticals shares in Q2 2024, an estimated $208K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 33 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Madrigal Pharmaceuticals position peaked at $540K in Q2 2018.
- 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2024.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.